<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349919</url>
  </required_header>
  <id_info>
    <org_study_id>002-TOI-2014-01</org_study_id>
    <nct_id>NCT02349919</nct_id>
  </id_info>
  <brief_title>Effect of Oral Procaterol on Postinfectious Persistent Cough</brief_title>
  <official_title>Effect of Oral Procaterol on Chronic Persistent Cough Following Upper Respiratory Tract Infection: Double-Blind Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thai Otsuka Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effectiveness of oral procaterol in treatment
      of non-asthmatic patients who suffer from persistent cough following upper respiratory tract
      infection (URTI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent cough following upper respiratory tract infection (URTI) is a common problem in
      the clinical practice, namely post-infectious cough. The potential mechanisms are
      viral-induced airway epithelial damage that leads to 1) airway hyperresponsiveness and airway
      narrowing, 2) increase in vascular permeability resulting in airway edema, and 3) activation
      of inflammatory mediators from inflammatory cells resulting in airway smooth muscle
      contraction. It is usually spontaneously resolved, although various therapeutic trials have
      been used with unpredictable results. Regarding to bronchodilators, inhaled ipratropium was
      effective in reducing cough symptom in a small study (N=14). We conduct a double-blind
      randomized placebo-controlled trial to investigate the effectiveness of oral procaterol, as a
      bronchodilator, in non-asthmatic adult patients suffering from persistent cough post URTI.

      Eligible patients who have cough lasting longer than 3 weeks post URTI with normal spirometry
      will be randomized to receive either placebo or procaterol (25 microgram twice daily) for 4
      weeks.

      The primary outcome is cough symptom score using Leicester cough questionnaire (LCQ). The
      secondary outcomes are pulmonary function tests (spirometry, impulse oscillometry) and
      exhaled nitric oxide and quality of life (SF-36). All outcomes are measured at baseline, 2
      weeks, and 4 weeks. Bronchoprovocation test with methacholine is performed at baseline and 4
      weeks to determine the provocative concentration of methacholine that induces falling of FEV1
      &gt;or =20%. Adverse events will be recorded every visit.

      Data analysis will be in both intention-to-treat and per-protocol fashion. A linear
      mixed-effect regression model will be applied to assess treatment effect on LCQ score, SF-36,
      and lung function. Within-subject variation will be fitted in the model as random effects
      whereas the treatment will be considered as a fixed effect. Time at measurement (i.e., 2- and
      4-week) will also be included in the mixed model by treating it as fixed-effect. Marginal
      treatment effects between treatments and time will be then estimated and compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total score from Leicester cough questionnaire</measure>
    <time_frame>up to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life score from SF-36</measure>
    <time_frame>2 weeks and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometric parameters (FEV1, Forced expiratory flow between 25% and 75% of vital capacity; FEF25-75%)</measure>
    <time_frame>2 weeks and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impulse oscillometry parameters (airway resistance at 5 Hz, and 20 Hz, difference of airway resistance at 5 Hz and 20 Hz)</measure>
    <time_frame>2 weeks and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provocative concentration of methacholine that induces falling of FEV1 &gt; or= 20% (PC20)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Cough</condition>
  <arm_group>
    <arm_group_label>Procaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procaterol</intervention_name>
    <description>Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks</description>
    <arm_group_label>Procaterol</arm_group_label>
    <other_name>procaterol hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice daily for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Having persistent cough that lasts longer than 3 weeks following URTI

          2. Currently being a non-smoker

          3. Having normal spirometry (FEV1&gt;or= 80% predicted)

          4. Obtain consent form

        Exclusion Criteria:

          1. Having cough more than 8 weeks

          2. Having history of allergic or intolerance to β2 agonist

          3. Having diagnosis of asthma by physicians

          4. Presence of wheeze or rhonchi on physical examination

          5. Having radiographic evidence of pneumonia, tuberculosis or sinusitis

          6. Having significant gastroesophageal reflux symptoms suggested by GERD-Q questionnaire
             (GERD-Q score &gt; 8)

          7. Currently taking ACE-inhibitor

          8. Being active smokers

          9. Refuse to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prapaporn Pornsuriyasak, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmonary and Critical Care, Department of Medicine, Ramathibodi Hospital, Mahidol University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theerasuk Kawamatawong, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Pulmonary and Critical Care, Department of Medicine, Ramathibodi Hospital, Mahidol University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Poungrat Thungtitigul, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pulmonary and Critical Care, Department of Medicine, Ramathibodi Hospital, Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prapaporn Pornsuriyasak, M.D.</last_name>
    <phone>6622021629</phone>
    <phone_ext>19</phone_ext>
    <email>pprapaporn@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nutthanun Pongpanich</last_name>
    <phone>6624019560</phone>
    <phone_ext>1023</phone_ext>
    <email>nutp@thai-otsuka.co.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prapaporn Pornsuriyasak, M.D.</last_name>
      <phone>662011629</phone>
      <phone_ext>19</phone_ext>
      <email>pprapaporn@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Theerasuk Kawamatawong, M.D.</last_name>
      <phone>662011629</phone>
      <email>ktheerasuk@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Hegele RG, Hayashi S, Hogg JC, Paré PD. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med. 1995 May;151(5):1659-64; discussion 1664-5. Review.</citation>
    <PMID>7735630</PMID>
  </reference>
  <reference>
    <citation>Blair HT, Greenberg SB, Stevens PM, Bilunos PA, Couch RB. Effects of rhinovirus infection of pulmonary function of healthy human volunteers. Am Rev Respir Dis. 1976 Jul;114(1):95-102.</citation>
    <PMID>180856</PMID>
  </reference>
  <reference>
    <citation>Empey DW, Laitinen LA, Jacobs L, Gold WM, Nadel JA. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis. 1976 Feb;113(2):131-9.</citation>
    <PMID>1247226</PMID>
  </reference>
  <reference>
    <citation>Nadel JA. Some epithelial metabolic factors affecting airway smooth muscle. Am Rev Respir Dis. 1988 Dec;138(6 Pt 2):S22-3.</citation>
    <PMID>3059901</PMID>
  </reference>
  <reference>
    <citation>Barnett K, Jacoby DB, Nadel JA, Lazarus SC. The effects of epithelial cell supernatant on contractions of isolated canine tracheal smooth muscle. Am Rev Respir Dis. 1988 Oct;138(4):780-3.</citation>
    <PMID>3202451</PMID>
  </reference>
  <reference>
    <citation>Ida S, Hooks JJ, Siraganian RP, Notkins AL. Enhancement of IgE-mediated histamine release from human basophils by viruses: role of interferon. J Exp Med. 1977 Apr 1;145(4):892-906.</citation>
    <PMID>67173</PMID>
  </reference>
  <reference>
    <citation>Busse WW, Swenson CA, Borden EC, Treuhaft MW, Dick EC. Effect of influenza A virus on leukocyte histamine release. J Allergy Clin Immunol. 1983 Apr;71(4):382-8.</citation>
    <PMID>6187791</PMID>
  </reference>
  <reference>
    <citation>Chonmaitree T, Lett-Brown MA, Grant JA. Respiratory viruses induce production of histamine-releasing factor by mononuclear leukocytes: a possible role in the mechanism of virus-induced asthma. J Infect Dis. 1991 Sep;164(3):592-4.</citation>
    <PMID>1714484</PMID>
  </reference>
  <reference>
    <citation>Volovitz B, Faden H, Ogra PL. Release of leukotriene C4 in respiratory tract during acute viral infection. J Pediatr. 1988 Feb;112(2):218-22.</citation>
    <PMID>3339502</PMID>
  </reference>
  <reference>
    <citation>SALEM H, AVIADO DM. ANTITUSSIVE DRUGS, WITH SPECIAL REFERENCE TO A NEW THEORY FOR THE INITATION OF THE COUGH REFLEX AND THE INFLUENCE OR BRONCHODILATORS. Am J Med Sci. 1964 May;247:585-600. Review.</citation>
    <PMID>14158494</PMID>
  </reference>
  <reference>
    <citation>Hueston WJ. A comparison of albuterol and erythromycin for the treatment of acute bronchitis. J Fam Pract. 1991 Nov;33(5):476-80.</citation>
    <PMID>1940815</PMID>
  </reference>
  <reference>
    <citation>Pornsuriyasak P, Charoenpan P, Vongvivat K, Thakkinstian A. Inhaled corticosteroid for persistent cough following upper respiratory tract infection. Respirology. 2005 Sep;10(4):520-4.</citation>
    <PMID>16135178</PMID>
  </reference>
  <reference>
    <citation>Fuller RW, Jackson DM. Physiology and treatment of cough. Thorax. 1990 Jun;45(6):425-30. Review.</citation>
    <PMID>2203180</PMID>
  </reference>
  <reference>
    <citation>Holmes PW, Barter CE, Pierce RJ. Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection. Respir Med. 1992 Sep;86(5):425-9.</citation>
    <PMID>1462022</PMID>
  </reference>
  <reference>
    <citation>Fujimura M, Sakamoto S, Kamio Y, Bando T, Kurashima K, Matsuda T. Effect of inhaled procaterol on cough receptor sensitivity to capsaicin in patients with asthma or chronic bronchitis and in normal subjects. Thorax. 1993 Jun;48(6):615-8.</citation>
    <PMID>8346491</PMID>
  </reference>
  <reference>
    <citation>Eldon MA, Battle MM, Coon MJ, Nordblom GD, Sedman AJ, Colburn WA. Clinical pharmacokinetics and relative bioavailability of oral procaterol. Pharm Res. 1993 Apr;10(4):603-5.</citation>
    <PMID>8483846</PMID>
  </reference>
  <reference>
    <citation>Raj AA, Pavord DI, Birring SS. Clinical cough IV:what is the minimal important difference for the Leicester Cough Questionnaire? Handb Exp Pharmacol. 2009;(187):311-20. doi: 10.1007/978-3-540-79842-2_16.</citation>
    <PMID>18825348</PMID>
  </reference>
  <reference>
    <citation>Becker LA, Hom J, Villasis-Keever M, van der Wouden JC. Beta2-agonists for acute bronchitis. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD001726. doi: 10.1002/14651858.CD001726.pub4. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD001726.</citation>
    <PMID>21735384</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postinfectious cough, postviral cough</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Procaterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

